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Shahid Javed Husain1, Nisar Rao1 and Javaid Ahmad Khan1

Abstract
Background: Leukotriene receptor antagonists (LTRAs) are well established in the management of outpatient
asthma. However, there is very little information as to their role in acute asthma exacerbations. We hypothesized
that LTRAs may accelerate lung function recovery when given in an acute exacerbation.
Methods: A randomized, double blind, placebo-controlled trial was conducted at the Aga Khan University Hospital
to assess the efficacy of oral montelukast on patients of 16 years of age and above who were hospitalized with
acute asthma exacerbation. The patients were given either montelukast or placebo along with standard therapy
throughout the hospital stay for acute asthma. Improvements in lung function and duration of hospital stay were
monitored.
Results: 100 patients were randomized; their mean age was 52 years (SD +/− 18.50). The majority were females
(79%) and non-smokers (89%). The mean hospital stay was 3.70 ± 1.93 days with 80% of patients discharged in
3 days. There was no significant difference in clinical symptoms, PEF over the course of hospital stay (p = 0.20 at
day 2 and p = 0.47 at day 3) and discharge (p = 0.15), FEV1 at discharge (p = 0.29) or length of hospital stay (p = 0.90)
between the two groups. No serious adverse effects were noted during the course of the study.
Conclusion: Our study suggests that there is no benefit of addition of oral montelukast over conventional treatment in
the management of acute asthma attack.
Trial registration: 375-Med/ERC-04
Keywords: Asthma attack, Leukotriene receptor antagonist, Montelukast, PEF, FEV1

Background
Acute asthma accounts for nearly 2 million emergency
department visits and 500,000 admissions each year in
the US, frequently ranking as a major contributor to
time away from work and decreased productivity [1]. Its
incidence is on the rise all across the world, especially in
the pediatric population, with bronchial asthma accounting for 4% of the pediatric out-patient visits [2,3]. A
multi-country survey has demonstrated a rise in asthma
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symptoms from 8.5% to 11.7% in 13–14 year old Pakistani
children, over a 6 year period [4].
Asthma is associated with chronic airway inflammation with recruitment of a number of inflammatory cells
including T-cells, mast cells and eosinophils. The macrophages, eosinophils and mast cells in particular have the
capacity to synthesize cysteinyl leukotrienes. The interaction of these mediators with the Type 1 cysteinyl leukotriene (CysLT) receptors, located on inflammatory
cells and the structural cells of the airways, is implicated
in inflammatory cell infiltration, initiation of bronchial
smooth muscle contraction, mucus secretion and increased vascular permeability that ultimately leads to airway narrowing [5].
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Montelukast is the most commonly used cysteinyl leukotrienes receptor 1 (CysLT-1) antagonist. It has been
shown to improve symptoms and lung function (FEV1)
within 15 minutes of administration in chronic asthma
with its effects lasting for a period of at least 24 hours [6].
The existing therapeutic modalities for acute asthma
include oxygen and short acting β2 agonist bronchodilators in order to promptly reverse airflow obstruction [7].
The systemic corticosteroids are recommended for exacerbations that are unresponsive to initial therapeutic
measures but studies have shown a 4–6 hour delay in
the onset of the effects of steroid therapy [8]. Such a
delay can prove to be catastrophic in the 30% of patients
who fail to respond to initial therapy by short acting
β2-agonists [9]. Furthermore, an increased rate of relapse following an acute exacerbation persists even
with corticosteroid therapy [10,11] with an estimated
10% rate of relapse within 7 days of discharge from the
emergency room (ER) and a 31% recurrence rate 10 to
21 days after discharge [12-15].
In our study, we tested the hypothesis that treatment with
a leukotriene receptor antagonist (LTRA), montelukast sodium would improve airway obstruction and clinical
outcomes in acute asthma exacerbation and would
subsequently decrease the duration of hospital stay.

Methods
Study setting

The patients were identified from the Aga Khan University Hospital (AKUH), located in Karachi, the largest
metropolitan city of Pakistan. This is a 650-bed, internationally accredited tertiary care hospital that caters to
the needs of a large multi-ethnic urban population. The
hospital has a dedicated emergency room (ER) and a 5-bed
respiratory special care unit staffed by a team of physicians
and nurses trained in the management of respiratory
disorders.
Study subjects

All patients of age 16 and above who presented to the
AKUH with acute asthma exacerbation were screened
for enrollment in the study. Informed consent was
obtained. The eligibility criteria included a diagnosis of
acute asthma exacerbation that required hospitalization
as defined by the Global Initiative for National Asthma
(GINA) Guidelines [7]. The criteria for hospitalization
was FEV1 < 70% predicted or PEF < 300 L/min after 30 minutes of receiving initial treatment in the ER, respiratory rate > 24 breaths/min and no improvement in
symptoms such as shortness of breath or wheezing.
The patients with the following conditions were excluded from the study; age <15 years, pregnancy, FEV1 >
70% predicted or PEF > 300 L/min, a history of tobacco
use of >10 years, concomitant therapy with systemic
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corticosteroids or leukotriene modifiers at any time in
the past 4 weeks at the time of admission, any concurrent acute medical condition like myocardial infarction,
congestive cardiac failure, diabetic ketoacidosis or shock,
acute respiratory failure requiring mechanical ventilation, and improvement in symptoms after being recruited
into the study warranting discharge from the emergency
department. Patients who were unwilling to consent
were also excluded. Flow chart of the study is shown
in Figure 1.
Study design

This was a randomized, double-blind, placebo controlled
parallel group drug trial conducted over a period of two
years from February 2006 to February 2008. All patients
presenting either to the emergency department or outpatient clinics of the AKUH requiring hospitalization
with acute asthma exacerbation were screened for inclusion in the study. The study was approved by the Ethical
Review Committee (ERC) of the Aga Khan University
(375-Med/ERC-04). A written informed consent was
obtained before enrollment and findings were shared
with subjects interested in the study outcome on clinic
follow-up. The patients underwent a baseline spirometry
and peak expiratory flow (PEF) testing soon after enrollment. A brief questionnaire was used to obtain information about the duration, severity and treatment of
asthma.
Measurement

The bedside spirometry was done using PiKo-1 (ATS
and EU electronic peak flow monitor, Ferraris Respiratory Europe Ltd., Westford SG13 7NW, UK) software
which measures the PEF and FEV1. The PiKo-1 test was
repeated three times. The primary aim of utilizing the
software was to facilitate both patient and investigator
use. Each test was performed within three minutes of
the previous one. The spirometry was done on admission and discharge. Other investigations like chest radiographs and arterial blood gases (ABG’s) were done if
deemed necessary by the admitting team.
Sample size

A group sample size of 50 patients in treatment
(Montelukast) and 50 in placebo group achieved 80%
power to detect a mean difference of 0.3 liters between
the two groups with a mean of 2.2 [16] and standard deviation of 0.7 at 5% significance level using a two-sided
two-sample t-test. The required final target sample size
was 100 patients.
Randomization and blinding

The AKUH pharmacy played a pivotal role in the
randomization of patients. The trial coordinator at the
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Figure 1 Flow chart of the study.

AKUH pharmacy was the key person to maintain
randomization and blinding and was the only one to
know the treatment status of the patient. Allocation
numbers were generated and assigned to each patient
found eligible to be enrolled in the study. Patients were
distributed to each arm based on the allocated code.
Neither the evaluators, nor the on-call admitting team
were made aware of the actual treatment allocations.
The patients were randomly allocated to one of the
two study arms; patients in arm-1 received standard
therapy and oral montelukast sodium (10 mg once daily)
and those in arm-2 received standard therapy along with
a placebo.
Intervention

All patients with acute asthma underwent clinical assessment for severity of attack and received standard therapy
with oxygen and inhaled bronchodilators via jet nebulizer
with salbutamol 2.5 mg and ipratropium bromide 500
mcg mixed with 2 cc of normal saline every 15 to 30 minutes. The duration of the high dose bronchodilator

Figure 2 Trial design. ER: Emergency room.

therapy was variable (1–4 hours) and subsequently tapered to every 6 hours depending on the symptomatic response to therapy. A dose of systemic corticosteroids in
the form of hydrocortisone 200 mg IV was administered
in the ER followed by 100 mg every 6 hours. The steroids
were subsequently changed to oral prednisolone
0.5 mg/kg/day for 7 days. The trial design followed in
the ER is shown in Figure 2.
Additional asthma therapies with aminophylline and
magnesium sulphate were given on the discretion of the
admitting team when asthma exacerbation was not
responding to initial standard therapy after hospitalization.
Antibiotics were given only if there was clinical or radiological suspicion of bacterial infection like fever >101 °F,
purulent sputum production or clinical or radiological
signs of consolidation. The use of antibiotic was not
assessed in our study.
Patients in the treatment arm 1 received oral montelukast
10 mg first dose in the ER followed by 10 mg oral dose once
a day in evening for the duration of stay in the hospital. The
medication was started in the ER as soon as standard
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therapy was administered, informed consent was obtained
and a decision was made for hospitalization.
The placebo was of the same appearance (color and
size) and taste as the trial medication; it was prepared by
the Hilton Pharma after being approved by Ministry of
Health (MoH) Pakistan. The first dose was given in the
ER followed by once daily for a period of duration of
stay in the hospital. The trial coordinator in AKUH
pharmacy managed the storage and distribution of placebo. The serial peak expiratory flow (PEF) monitoring
was done; a baseline PEF value was obtained on enrolment, then at 30, 60 and 90 minutes from the baseline
value, followed by every 12 hours daily until discharge.
A minimum of 3 readings were obtained each time before administration of bronchodilator and the best of 3
was taken as the final value.
Outcome assessment

The primary outcomes of the study were a) improvement in lung function measured as PEF and FEV1 over
the course of hospital stay and discharge and b) duration
of hospital stay.
Secondary outcome included development of complications such as respiratory failure, cardiac arrest and/or
death.
Statistical analysis

For descriptive analysis mean ± standard deviation are
reported for continuous variables, and number (%) for
categorical variables. In univariate analyses, differences
in proportions for type of treatment groups were
assessed by using the Chi-square test or Fisher exact test
where appropriate. For contrasts of continuous variables,
independent sample t-test was used to assess the difference of means. All analyses were conducted by using the
Statistical package for social science (SPSS Release 15.0,
standard version, copyright © SPSS; 1989–02), p-values
were two sided and considered as statistically significant
if < 0.05.
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Table 1 Baseline characteristics of study patients
receiving montelukast and placebo (n = 100)
Number

Montelukast

Placebo

50

50

Age in years (SD)

50.50 ± 18.26

52.68 ± 18.86

Male: Female (n)

7:43

14:36

22 (44%)

22 (44%)

b. > 2 admissions

17 (34%)

11 (22%)

c. ICU admissions

03 (06%)

06 (12%)

d. Prior intubation

01 (02%)

04 (08%)

Family history of Asthma

30 (60%)

27 (54%)

24 (48%)

25 (50%)

Asthma history
a. Past history of sudden
severe exacerbations

Medication history
a) Fluticasone 250 mcg +
Salmeterol 25 mcg
b) Oral Theophylline

07 (14%)

11 (22%)

c) Inhaled anti-cholinergic

01 (02%)

02 (04%)

a) Infection

23 (46%)

22 (44%)

b) Weather change

27 (54%)

24 (48%)

c) Non-compliance to drugs

01 (02%)

01 (02%)

d) Allergen exposure

07 (14%)

10 (20%)

f) None

04 (07%)

02 (04%)

47 (94%)

42 (84%)

Precipitating factors

Smoking status
a) Non-smoker
b) Current smoker

02 (04%)

03 (06%)

c) Ex-smoker

01 (02%)

05 (10%)

a) IV aminophylline

03 (06%)

02 (04%)

b) IV magnesium sulphate

16 (32%)

15 (30%)

c) Oral theophylline

10 (20%)

16 (32%)

Additional therapy

Primary outcome measures

Results
In total, 160 patients with acute asthma exacerbation
were assessed for eligibility. Of the 100 enrolled patients,
50 were randomized to receive oral montelukast. The
baseline characteristics of both groups are given in
Table 1. Weather change was the major precipitating
factor of the acute asthma attack in 51% of the patients
followed by infection of the respiratory tract in 45% patients while 57 patients had a positive family history for
asthma. The majority of patients were non-smokers, 44
had a prior history of an acute exacerbation and 28 were
hospitalized 2 or more times in the past year with 9 requiring ICU admission and 5 requiring intubation and
mechanical ventilation as a result of the exacerbation.

There was no significant difference in the PEF between
both treatment groups during the hospital stay and at
discharge (Table 2 and Figure 3). The patients who received montelukast had a mean PEF of 160.12 ±
77.0 L/min while those on placebo had a mean PEF of
187.08 ± 108.9 L/min on discharge (p = 0.15). A similar
trend was seen in the FEV1 (p = 0.29), where the mean
values for the study and placebo groups were 1.07 ±
0.54 L/min and 1.21 ± 0.68 L/min respectively (Table 2).
There was no significant variation in the duration of
hospital stay between both the groups with the mean
duration for patients belonging to montelukast and placebo groups being 3.67 ± 1.86 days and 3.72 ± 2.02 days,
respectively (p = 0.90).
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Table 2 Peak expiratory flow (PEF) & forced expiratory
volume in 1 second (FEV1) in patients receiving
montelukast vs. placebo
Montelukast

Placebo

p
value

n

Mean (±SD)

n

Mean (±SD)

PEF at admission

50

123.82 (±48.76)

50

144.70 (±78.85)

0.11

PEF at day 2

50

149.48 ± 75.76

50

173.41 ± 103

0.20

PEF at day3

50

164.50 ±82.74

50

183.35 ± 113.12

0.47

PEF at discharge

50

160.12 (±77.00)

50

187.08 (±108.93)

0.15

FEV1 at admission

50

0.82 (±0.35)

50

0.90 (±0.60)

0.46

FEV1 at discharge

50

1.07 (±0.54)

50

1.21 (±0.68)

0.29

Secondary outcome measures

Two patients, one from each arm, developed respiratory
failure. No patient in either group was withdrawn due to
worsening asthma or adverse drug effect from the study.

Discussion
Our study did not reveal significant differences in pulmonary function tests measured as FEV1 at admission
and discharge and PEF measured at specific intervals or
length of hospital stay in patients hospitalized with acute
asthma exacerbation that were given oral montelukast
vs. placebo. The efficacy and tolerability profile of oral
montelukast were comparable to placebo and no serious
adverse effects were encountered.
The pathology of asthma triggers the arachnoid acid cascade
leading to formation of leukotrienes via the 5-lipoxygenase
pathway. The cysteinyl leukotrienes possess pro-inflammatory
characteristics which can directly cause or potentiate airflow obstruction by increased mucosal secretion and
bronchospasm [5,17]. Leukotriene pathway modifiers,
hence, are a subject of interest as a possible adjunct therapy in the acute management of asthma exacerbation.
However, our results are in contrast to data recently published by Ramsay et al. They randomized 73 patients and
found a significantly higher peak expiratory flows (PEFs)

Figure 3 Mean PEF values over the course of hospital stay
and discharge.

measured in the morning after admission in patients
who received montelukast (p = 0.046, 95% CI of 1.15113.6 L/min) as compared to patients who did not
[18]. A study by Silverman et al. evaluated the effects
of another LTRA, zafirlukast. They randomized patients into three groups; oral zafirlukast at 20 mg and
160 mg vs. placebo. They looked at the time to relapse
in the outpatient setting after discharge from the emergency department and found reduction in the absolute
rate of relapse by 5.3% in patients treated with
zafirlukast. They reported significant improvement in
FEV1 and dyspnea in the ER only with 160 mg of
zafirlukast [19]. Other studies have also looked into effects of intravenous montelukast in managing acute
asthma exacerbations. Camargo et al. randomized 201
patients to three groups with two receiving separate doses
of montelukast (7 mg and 14 mg) and one group receiving
placebo. They reported significantly higher FEV1 in patients receiving standard therapy with montelukast as
compared to placebo at 10 minutes (p = 0.03), 20 minutes
(p = 0.007) and two hours (p = 0.003) [20]. These results
were validated in a more recent study in Japan which
reported both IV monteleukast 7 mg and 14 mg to be effective as an adjunct therapy over 60 minutes; p < 0.05 and
p < 0.001 respectively [21].
To the best of our knowledge, our study is the first one
to report no added benefits of using montelukast in acute
asthma exacerbation in hospitalized adult population.
Other studies which report similar findings mostly correspond to the pediatric population [22-24]. Nelson et al.
[22] and Morris et al. [23] did not find any significant increase in FEV1 by using oral and intravenous montelukast
respectively while Todi et al. reported similar proportion
of children having Modified Pulmonary Index Score ≤ 9 in
both the study and control groups [24].
A possible reason we failed to find significant improvement is that we looked at PEFs early in the course of
hospitalization instead of FEV1 in comparison to the
positive studies cited above. Another reason for failure
of significant improvement might be the use of enteral
route of administration. However, Dockhorn et al.
conducted a study comparing the effectiveness of intravenous montelukast vs. oral montelukast vs. placebo in the
setting of acute asthma. Though intravenous montelukast
was quicker in onset of action with the mean percentage
change in FEV1 higher at earlier time intervals (15 mins to
1 hour), this difference decreased over the time and was
not significant (p > 0.05). Moreover, there was no difference
in mean maximum percentage change in FEV1 from
baseline between intravenous and oral montelukast
(p = 0.071) [6].
This study has several limitations. Firstly, our study sample is relatively small. Secondly, we excluded patients with
respiratory failure requiring positive pressure ventilation,
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either noninvasive or invasive. Both these factors may have
impacted on the strength of difference observed in the two
groups. Another limitation is the lack of biological surrogate markers like cysteinyl leukotrienes levels which have
been shown to be higher in states of acute asthma exacerbation [25]. It is possible that these levels may have reduced in the patients but did not translate into clinical
effectiveness yet. The use of Piko-1 pocket spirometer is
another limitation in our study. A study from Switzerland
revealed that the accuracy of Piko-1 spirometer is acceptable. However, it tended to underestimate FEV1 in the
lower range in 20 volunteers [26]. Lastly, this was a single
center study and hence, cannot be generalized to the whole
population.

Conclusion
Our study suggests that there is no added benefit of
using montelukast along with the standard therapy for
the management of acute asthma exacerbation in hospitalized adult population. We recommend that larger
scale multicenter trials would better help to evaluate the
role of cysteinyl leukotrienes antagonists in treating
acute exacerbations of asthma.
Abbreviations
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